Blockchain analytics firm Chainalysis has identified a growing trend among gray-market peptide drug suppliers turning to Bitcoin and stablecoins as preferred payment methods. The shift highlights new challenges for crypto compliance teams and law enforcement agencies tracking transactions that fall into regulatory gray areas.
Source: Read the original article
